Description
A JAX inhibitor (IC50s = 6.1, 12, and 8 nM for JAK1, JAK2, and JAK3, respectively); selective for JAK1-3 over ROCK-II and Lck (IC50s = 3,400 and 3,870 nM, respectively) as well as 28 additional kinases in enzyme assays (IC50s = >10,000 nM); inhibits IL-2-mediated phosphorylation of JAK3 and STAT5 (30 ng/ml); prevents rejection and prolongs survival in murine and cynomolgus monkey models of heterotopic heart and kidney transplantation
Formal name: 2-hydroxy-1,2,3-propanetricarboxylate-4-methyl-3R-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4R-ylamino)-β-oxo-1-piperidinepropanenitrile
Synonyms: Tofacitinib citrate
Molecular weight: 504.5
CAS: 540737-29-9
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Signaling|JAK Signaling||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis||Research Area|Immunology & Inflammation|Gastric Disease|Ulcerative Colitis